JCIA
AMLX icon

Jackson Creek Investment Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,193
Closed -$498K – 306
2023
Q3 		$498K Sell
27,193
-25
-0.1% -$529 0.21% 225
2023
Q2 		$587K Buy
27,218
+1,972
+8% +$53.3K 0.23% 216
2023
Q1 		$741K Buy
+25,246
New +$877K 0.31% 178

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jackson Creek Investment Advisors's AMLX Position: Q4 2023 in Review

Jackson Creek Investment Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 27,193 shares — an estimated $498K sold.

Jackson Creek Investment Advisors first reported a position in AMLX in Q1 2023 and held it in 3 quarters. The position peaked at $741K in Q1 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Jackson Creek Investment Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 27,193 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $498K.
  • Jackson Creek Investment Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Jackson Creek Investment Advisors's Amylyx Pharmaceuticals position peaked at $741K in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Jackson Creek Investment Advisors's 13F filing for Q4 2023, filed 5 Feb 2024.